Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Pharmacy, physical therapy, occupational therapy, and physician assistant professional students' perspectives on interprofessional roles and responsibilities.

Wynarczuk KD, Hadley DE, Sen S, Ward JF, Ganetsky VS, Sen S.

J Interprof Care. 2019 Jan 28:1-4. doi: 10.1080/13561820.2019.1572599. [Epub ahead of print]

PMID:
30686079
2.

Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.

van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ.

World J Urol. 2019 Jan 22. doi: 10.1007/s00345-019-02636-7. [Epub ahead of print]

3.

Detection and Treatment of Primary Prostatic Melanoma.

Li R, Zhang M, Duplisea JJ, Troncoso P, Ward JF.

Urology. 2019 Jan;123:16-19. doi: 10.1016/j.urology.2018.08.035. Epub 2018 Sep 5. Review.

PMID:
30195014
4.

Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research.

Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):524-532. doi: 10.1038/s41391-018-0056-7. Epub 2018 Jul 9.

PMID:
29988098
5.

A pilot IPE workshop integrating OT, pharmacy, PT, and PA programs.

Hadley DE, Pitonyak JS, Wynarczuk KD, Sen S, Ward JF, Patel RV.

Curr Pharm Teach Learn. 2018 Feb;10(2):220-225. doi: 10.1016/j.cptl.2017.10.012.

PMID:
29706279
6.

Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.

Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF.

Eur Urol. 2018 Aug;74(2):140-143. doi: 10.1016/j.eururo.2018.03.031. Epub 2018 Apr 12.

PMID:
29656854
7.

Characterization of Glomus Tumors of the Kidney.

Li R, Petros FG, Davis CJ Jr, Ward JF.

Clin Genitourin Cancer. 2017 Sep 7. pii: S1558-7673(17)30277-X. doi: 10.1016/j.clgc.2017.09.002. [Epub ahead of print] No abstract available.

PMID:
28967505
8.

Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort.

Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA.

BJU Int. 2018 Apr;121(4):540-548. doi: 10.1111/bju.14021. Epub 2017 Oct 17.

9.

Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1.

Raven F, Ward JF, Zoltowska KM, Wan Y, Bylykbashi E, Miller SJ, Shen X, Choi SH, Rynearson KD, Berezovska O, Wagner SL, Tanzi RE, Zhang C.

EBioMedicine. 2017 Oct;24:93-101. doi: 10.1016/j.ebiom.2017.08.028. Epub 2017 Sep 4.

10.

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes.

Metcalfe MJ, Troncoso P, Guo CC, Chen HC, Bozkurt Y, Ward JF, Pisters LL.

Can Urol Assoc J. 2017 Jul;11(7):E277-E284. doi: 10.5489/cuaj.4304. Epub 2017 Jul 11.

11.

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J.

BJU Int. 2018 Jan;121(1):69-76. doi: 10.1111/bju.13963. Epub 2017 Aug 16.

12.

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P.

Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27.

13.

Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients.

Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, Ganzer R, Chapet O, Gelet A, Chaussy CG, Robertson CN, Thuroff S, Ward JF.

BJU Int. 2017 Jun;119(6):896-904. doi: 10.1111/bju.13766. Epub 2017 Mar 10.

14.

Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.

Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM.

Oncotarget. 2016 Dec 27;7(52):86280-86289. doi: 10.18632/oncotarget.13380.

15.

Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease.

Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, Chang EB, Tanzi RE, Sisodia SS.

Sci Rep. 2016 Jul 21;6:30028. doi: 10.1038/srep30028.

16.

Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy.

Kenney PA, Nawaf CB, Mustafa M, Wen S, Wszolek MF, Pettaway CA, Ward JF, Davis JW, Pisters LL.

Can J Urol. 2016 Jun;23(3):8271-7.

17.

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P.

EBioMedicine. 2016 May;7:85-93. doi: 10.1016/j.ebiom.2016.03.047. Epub 2016 Apr 7.

18.

Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.

Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SE.

Eur Urol. 2017 Mar;71(3):476-482. doi: 10.1016/j.eururo.2016.05.017. Epub 2016 May 24.

PMID:
27234998
19.

Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.

Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL.

Cancer. 2016 Jun 15;122(12):1836-43. doi: 10.1002/cncr.29996. Epub 2016 Mar 28.

21.

The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer.

Mustafa M, Delacroix S, Ward JF, Pisters L.

World J Surg Oncol. 2015 Dec 21;13:340. doi: 10.1186/s12957-015-0753-9.

22.

Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System.

Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF.

Clin Genitourin Cancer. 2016 Apr;14(2):130-8. doi: 10.1016/j.clgc.2015.10.008. Epub 2015 Oct 24.

PMID:
26558524
23.

Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design.

van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ.

Urol Oncol. 2015 Nov;33(11):495.e1-7. doi: 10.1016/j.urolonc.2015.06.015. Epub 2015 Jul 29.

PMID:
26231310
24.

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):276-80. doi: 10.1038/pcan.2015.23. Epub 2015 May 26.

25.

Active surveillance monitoring: the role of novel biomarkers and imaging.

Ward JF, Eggener SE.

Asian J Androl. 2015 Nov-Dec;17(6):882-4; discussion 883. doi: 10.4103/1008-682X.156858. Review.

26.

Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.

Davis JW, Ward JF 3rd, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J.

BJU Int. 2016 Jul;118(1):68-76. doi: 10.1111/bju.13193. Epub 2015 Jul 4.

27.

Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance.

Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J.

BJU Int. 2016 Mar;117(3):469-77. doi: 10.1111/bju.13099. Epub 2015 Apr 21.

28.

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.

Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC.

J Hematol Oncol. 2014 Aug 1;7:52. doi: 10.1186/s13045-014-0052-x.

29.

Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic.

Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE.

J Natl Compr Canc Netw. 2014 Jul;12(7):993-8.

30.

Health technology assessment in evolution - focal therapy in localised prostate cancer.

Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward JF, Ahmed HU.

Expert Rev Anticancer Ther. 2014 Nov;14(11):1359-67. doi: 10.1586/14737140.2014.932692. Epub 2014 Jun 25. Review.

PMID:
24965212
31.

Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts ("ICE").

Reis LO, Billis A, Zequi SC, Tobias-Machado M, Viana P, Cerqueira M, Ward JF.

Aging Male. 2014 Jun;17(2):66-71. doi: 10.3109/13685538.2014.895319. Epub 2014 Mar 6. Review.

PMID:
24597940
32.

Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.

van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT.

Eur Urol. 2014 Jun;65(6):1078-83. doi: 10.1016/j.eururo.2014.01.001. Epub 2014 Jan 13.

PMID:
24444476
33.

Considerations for patient selection for focal therapy.

Ward JF, Pisters LL.

Ther Adv Urol. 2013 Dec;5(6):330-7. doi: 10.1177/1756287213496127. Review.

34.

Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry.

Ward JF, DiBlasio CJ, Williams C, Given R, Jones JS.

BJU Int. 2014 May;113(5):714-8. doi: 10.1111/bju.12476. Epub 2014 Jan 22.

35.

Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma.

Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA.

BJU Int. 2013 Jun;111(7):1068-74. doi: 10.1111/j.1464-410X.2012.11729.x. Epub 2013 Apr 2.

36.

PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF.

J Urol. 2013 Jul;190(1):64-9. doi: 10.1016/j.juro.2013.02.018. Epub 2013 Feb 14.

PMID:
23416644
37.

The impact of past introductions on an iconic and economically important species, the red deer of Scotland.

Pérez-Espona S, Hall RJ, Pérez-Barbería FJ, Glass BC, Ward JF, Pemberton JM.

J Hered. 2013 Jan-Feb;104(1):14-22. doi: 10.1093/jhered/ess085. Epub 2012 Oct 22.

PMID:
23091222
38.

Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy.

Leibovici D, Chiong E, Pisters LL, Guo CC, Ward JF, Andino L, Prokhorova IN, Troncoso P.

J Urol. 2012 Jul;188(1):98-102. doi: 10.1016/j.juro.2012.02.2571. Epub 2012 May 12.

PMID:
22578724
39.

Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry.

Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, Conti GN, Ganzer R, Pasticier G, Thuroff S, Ward JF.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):256-9.

PMID:
22487909
40.

Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans.

Shih YC, Ward JF, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS.

Value Health. 2012 Mar-Apr;15(2):367-75. doi: 10.1016/j.jval.2011.10.008. Epub 2011 Dec 16.

41.

Focal therapy for the treatment of localized prostate cancer: a potential therapeutic paradigm shift awaiting better imaging.

Ward JF 3rd, Rewcastle JC, Ukimura O, Gill IS.

Curr Opin Urol. 2012 Mar;22(2):104-8. doi: 10.1097/MOU.0b013e3283501813. Review.

PMID:
22273756
42.

Is transureteroureterostomy performed during multi-organ resection for non-urothelial malignancy safe and effective?

Pisters PW, Pettaway CA, Liu P, Matin SF, Ward JF, Leibovici D.

J Surg Oncol. 2012 Jul 1;106(1):62-5. doi: 10.1002/jso.23039. Epub 2012 Jan 18.

PMID:
22259198
43.

Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.

Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA.

J Surg Res. 2012 Jul;176(1):147-53. doi: 10.1016/j.jss.2011.09.017. Epub 2011 Oct 5.

PMID:
22099584
44.

Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry.

Ward JF, Jones JS.

BJU Int. 2012 Jun;109(11):1648-54. doi: 10.1111/j.1464-410X.2011.10578.x. Epub 2011 Oct 28.

45.

Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.

Dhar N, Ward JF, Cher ML, Jones JS.

BJU Int. 2011 Aug;108(4):508-12. doi: 10.1111/j.1464-410X.2011.10238.x. Epub 2011 Jul 1.

46.

Seasonal luteal cyclicity of pubertal and adult red deer (Cervus elaphus).

Asher GW, Scott IC, Archer JA, Ward JF, Littlejohn RP.

Anim Reprod Sci. 2011 May;125(1-4):138-47. doi: 10.1016/j.anireprosci.2011.03.009. Epub 2011 Mar 23.

PMID:
21497465
47.

High-intensity focused ultrasound for therapeutic tissue ablation in surgical oncology.

Ward JF.

Surg Oncol Clin N Am. 2011 Apr;20(2):389-407, ix. doi: 10.1016/j.soc.2010.11.009. Review.

PMID:
21377590
48.

Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.

Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A.

BJU Int. 2011 Oct;108(8 Pt 2):E196-201. doi: 10.1111/j.1464-410X.2011.10091.x. Epub 2011 Feb 18.

49.

Effect of melatonin implants on the incidence and timing of puberty in female red deer (Cervus elaphus).

Asher GW, Archer JA, Ward JF, Scott IC, Littlejohn RP.

Anim Reprod Sci. 2011 Feb;123(3-4):202-9. doi: 10.1016/j.anireprosci.2010.11.018. Epub 2010 Dec 7.

PMID:
21190800
50.

Prostate cancer: HIFU is effective, but associated morbidity still remains unclear.

Ward JF.

Nat Rev Urol. 2010 Nov;7(11):597-8. doi: 10.1038/nrurol.2010.176. No abstract available.

PMID:
21068758

Supplemental Content

Support Center